Dr. iur. Alain P. Röthlisberger, LL.M. (LSE), MBA

Switzerland

Dr. iur. Alain P. Röthlisberger, LL.M. (LSE), MBA

Dr. Alain P. Röthlisberger acts as partner and independent board member, focusing on strategy, corporate and commercial law, M&A and regulatory matters. He is heading the firm's Middle East Desk and its Financial Intermediary Services. He has a proven record of more than 25 years of experience as an attorney at law, corporate and general counsel and head legal and compliance in the fields of financial and capital markets law, securities regulation (including disclosure & takeover regulation), banking law, FinTech, commercial law, employment law, corporate law & corporate governance, joint ventures and cross-border M&A, all regarding transactions in Switzerland, Europe, North Africa, the Middle East, Asia (including China) and the US. He is an author of numerous books and articles on corporate law & corporate governance, securities regulation, banking and capital markets law as well as criminal procedure. Voluntary work entails activities as lecturer at HWZ University of Applied Sciences Zurich on legal and regulatory aspects of FinTech and expert function "Financial Services" at Swiss Integrity Commission.

Details

  • Independent board member and chairman of various companies
  • Lecturer at HWZ University of Applied Sciences Zurich on legal & regulatory aspects of FinTech
  • Expert function "Financial Services" at the Swiss Integrity Commission
  • Head of the Middle East Desk
  • Head of the regulated Financial Services Desk
  • Colonel, Swiss Armed Forces (Staff Operational Training)
  • "Regulierung von Bitcoin, Krypto und ICOs: Wie geht es weiter?" (FuW No. 19 of 10 March 2018, supplement "Anlegen mit Weitsicht", p. 12 et seq.)
  • "Bahn frei für Fintechs" (FuW No. 19 of 11 March 2017, supplement "Anlegen mit Weitsicht", p. 16 et seq.)
  • "Regulierung für mehr Kundenschutz" (10x10 – The ETF & ETP Newsletter No. 4 of 17 May 2016, p. 10 et seq.)
  • "Wettbewerbsfähigkeit stärken" (FuW No. 22 of 19 March 2016, supplement "Anlegen mit Weitsicht", p. 18)
  • "Regulierungen werden überschaubarer" (FuW No. 20 of 14 March 2015, supplement "Anlegen mit Weitsicht", p. 22)
  • "Stimmrechtsaktien – ein alter Hut?" (FuW No. 53 of 4 July 2012, p. 14)
  • "Retrozessionen im Regulierungsfokus" (10x10 – The ETF Newsletter No. 1 of 14 February 2011, p. 7)
  • "Systemwechsel zum Kapitaleinlageprinzip – Steuerfreie Ausschüttung an die Aktionäre aus Reserven aus Kapitaleinlagen seit Anfang Jahr möglich – Handhabung im künftigen Aktienrecht noch offen" (FuW No. 1 of 5 January 2011, p. 20)
  • "Rechte aus Bucheffekten bleiben unberührt – Am 1. Januar 2010 tritt das Bucheffektengesetz in Kraft – Grundlage für die mediatisierte Wertpapierverwahrung – Bucheffekten als neues Rechtsinstrument" (FuW No. 100 of 23 December 2009, p. 21)
  • Commentary on sec. 114-116, 118, 195-198 MStP in "Kommentar zum Militärstrafprozess" (Zurich, 2008)
  • "Die EBK erhöht auf Anfang 2008 die Anforderungen an Corporate Governance von Banken und Effektenhändlern – Anforderungen an Compliance und Risikokontrolle definiert" (FuW No. 101 of 29 December 2007, p. 24)
  • "Ad hoc-Publizität – Die Verantwortung verbleibt beim Emittenten" (FuW No. 78 of 4 October 2006, supplement "Investor Relations", p. 10)
  • "Transparenzvorlage – Investoren können den Verwaltungsrat effizienter kontrollieren" (FuW No. 36 of 8 October 2005, p. 26)
  • "Offenlegung von Management-Transaktionen – Signaleffekte für die Anleger?" (FuW No. 36 of 7 May 2005, p. 27)
  • "Verschärfen revidierte Ad hoc-Bestimmungen die Praxis der SWX Swiss Exchange?" (FuW No. 7 of 26 January 2005, p. 23)
  • MBA Thesis "Defending against a Hostile Bid – A Defence Support Manual for SWX Swiss Exchange Listed Companies" (SnA No. 20, Zurich 2004)
  • "Emissionsprogramme künftig in der Schweiz registrieren – Eine Chance für den Anleihenmarkt" (FuW No. 67 of 25 August 2004, p. 5)
  • "US-Gesetze und Kotierungsreglement dämpfen den Wegfall des Verankerungsprinzips" (FuW No. 28 of 10 April 2004, p. 5)
  • "Was unterscheidet ein MTN Programm von einer Stand-alone-Emission?" (FuW No. 11 of 8 February 2003, p. 5)
  • "Die Schweiz kennt keine Verkaufsrestriktionen für Anleihensobligationen" (FuW No. 85 of 11 September 2002, p. 5)
  • LL.M.-Dissertation "Disclosure of Interests in Shares: A Comparative Analysis United Kingdom – Switzerland" (SnA No. 14, Zurich 1998)
  • Doctoral Thesis (PhD) "Offenlegung der Beteiligungsverhältnisse bei Publikumsgesellschaften" (ASR No. 612, Bern 1998)
  • Licentiate Thesis "Die Abschaffung von Stimmrechtsaktien" (SSHW No. 202, Zurich 2000)
  • Attorney-at-law (Swiss bar admission, 1994, top 10 ranking)
  • Partner at act legal Switzerland (since 2021, formerly BGPartner Ltd)
  • Activities as attorney as well as Corporate Counsel, Head Legal & Compliance and General Counsel in Swiss and international listed companies, most recently as Group General Counsel of Almarai Company, KSA
  • University of Zurich, MBA (summa cum laude and best in class award)
  • Stanford University Graduate School of Business, Strategic Management
  • International Air Transport Association, Diploma in Air Law (distinction)
  • London School of Economics and Political Science, LL.M. in International Business Law (merit)
  • University of Bern, Dr. iur. (magna cum laude)
  • German
  • English
  • French

news

track-records

Advising ICAS World Limited on the acquisition of 100% of ICAS Schweiz AG and its subsidiaries in Germany, France, Italy, Austria and Luxembourg.

Advising ICAS World Limited on the acquisition of 100% of ICAS Schweiz AG and its subsidiaries in Germany, France, Italy, Austria and Luxembourg.

Advising SIX-listed Lalique Group SA on its 2024 Annual General Meeting, including the shareholder vote on the delisting of its shares.

Advising SIX-listed Lalique Group SA on its 2024 Annual General Meeting, including the shareholder vote on the delisting of its shares.

Advising Swedish listed SynAct Pharma AB on the acquisition of all shares in Swiss biotech company TXP Pharma AG.

Advising Swedish listed SynAct Pharma AB on the acquisition of all shares in Swiss biotech company TXP Pharma AG.

Advising Lafayette Mittelstand Capital on the acquisition of a majority stake in Diametal Group, an international manufacturer of high-precision cutting tools and super abrasives.

Advising Lafayette Mittelstand Capital on the acquisition of a majority stake in Diametal Group, an international manufacturer of high-precision cutting tools and super abrasives.

Dr. iur. Alain P. Röthlisberger, LL.M. (LSE), MBA

Share via email

act legal BGPartner Ltd
Monbijoustrasse 61
CH-3001 Bern
Switzerland

act legal BGPartner Ltd
General-Guisan-Quai 38
CH-8027 Zurich
Switzerland

Go to
Offices

Go to Offices